×
ADVERTISEMENT

OCTOBER 4, 2024

FDA Approves Neoadjuvant/Adjuvant Opdivo for Resectable NSCLC

Originally published by our sister publication Clinical Oncology News

By Clinical Oncology News Staff

The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥4 cm and/or node-positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase